Alterity Therapeutics Ltd (NAS:ATHE)
$ 1.9 -0.05 (-2.58%) Market Cap: 16.50 Mil Enterprise Value: 16.64 Mil PE Ratio: 0 PB Ratio: 0.39 GF Score: 28/100

Alterity Therapeutics Ltd Share Series Monday Management Update Transcript

May 22, 2023 / 03:00PM GMT
Release Date Price: $2.73 (-5.87%)
Remy Bernarda
Investor Relations Advisory Solutions - IR

Good morning, everyone, and welcome back to the SHARE Series Monday management update. My name is Remy Bernarda, and I'm a partner with Investor Relations Advisory Solutions. I'm excited to introduce you to Alterity Therapeutics, a company that we believe has a compelling investment story as they are looking to make a meaningful difference in the lives of patients with a rare disease.

(Conference Instructions)

With that, let's get started. I would now like to introduce Dr. David Stamler, who is the CEO of Alterity Therapeutics. David, can you please provide a brief overview of Alterity as well as a short background on yourself and your team and your history at the company.

David Stamler
Alterity Therapeutics - CEO

Thank, Remy. Sure. Alterity is a global company with our US offices based in San Francisco and our international office based in Melbourne. We have a long history of developing drugs for neurodegenerative diseases. And I joined the company in 2017, originally as the Chief

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot